Global Parenteral Nutrition-Associated Cholestasis Treatment Market, By Drugs (Lipid Injectable Emulsion, Fish Oil Triglyceride, Ursodeoxycholic Acid and Others), Treatment (Surgery, Drugs, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Parenteral Nutrition-Associated Cholestasis Treatment Market
The parenteral nutrition-associated cholestasis treatment market is expected to witness market growth at a rate of 4.95% in the forecast period of 2021 to 2028. Data Bridge Market Research report on parenteral nutrition-associated cholestasis treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The increase in the prevalence of various illnesses in infants globally is escalating the growth of parenteral nutrition-associated cholestasis treatment market.
Parenteral nutrition-associated cholestasis (PNAC) refers to a serious liver complication in preterm infants who are being administrated prolonged intravenous nutrition. Parenteral nutrition is defined as lifesaving intervention for many preterm infants other neonates suffering from severe illness. The prolonged administration of parenteral nutrition could lead to intrahepatic cholestasis. The condition tends to impair the release of digestive fluid called bile from liver cells which results in the accumulation of bile in the liver.
The increase in the number of people suffering from parenteral nutrition-associated cholestasis across the globe acts as one of the major factors driving the growth of parenteral nutrition-associated cholestasis treatment market. The high need of drugs such as lipid injectable emulsion, fish oil triglyceride, ursodeoxycholic acid and others, and surge in financial support by government to the researchers for developing novel intervention accelerate the market growth. The increase in vulnerable preterm infants receiving parenteral nutrition, and rise in in the number of acquisition strategies and company collaborations among manufacturers further influence the market. Additionally, rise in investment, developments in healthcare and increase in number of births positively affect the parenteral nutrition-associated cholestasis treatment market. Furthermore, rise in demand of disease specific novel treatment extend profitable opportunities to the market players in the forecast period of 2021 to 2028.
On the other hand, high cost associated with the treatment and diagnosis of parenteral nutrition-associated cholestasis is expected to obstruct the market growth. Lack of skilled expertise is projected to challenge the parenteral nutrition-associated cholestasis treatment market in the forecast period of 2021-2028.
This parenteral nutrition-associated cholestasis treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info parenteral nutrition-associated cholestasis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Parenteral Nutrition-Associated Cholestasis Treatment Market Scope and Market Size
The parenteral nutrition-associated cholestasis treatment market is segmented on the basis of drug, treatment, mode of administration, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug, the parenteral nutrition-associated cholestasis treatment market is segmented into lipid injectable emulsion, fish oil triglyceride, ursodeoxycholic acid and others.
- On the basis of treatment, the parenteral nutrition-associated cholestasis treatment market is segmented into surgery, drugs and others.
- On the basis of mode of administration, the parenteral nutrition-associated cholestasis treatment market is segmented into injectable, oral and others.
- On the basis of distribution channel, the parenteral nutrition-associated cholestasis treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
- On the basis of end user, the parenteral nutrition-associated cholestasis treatment market is segmented into hospitals, homecare, specialty clinics and others.
Parenteral Nutrition-Associated Cholestasis Treatment Market Country Level Analysis
The parenteral nutrition-associated cholestasis treatment market is analysed and market size information is provided by country, drug, treatment, mode of administration, distribution channel and end user as referenced above.
The countries covered in the parenteral nutrition-associated cholestasis treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the parenteral nutrition-associated cholestasis treatment market due to the increase in drug approvals within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the developments in health care infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The parenteral nutrition-associated cholestasis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Parenteral Nutrition-Associated Cholestasis Treatment Market Share Analysis
The parenteral nutrition-associated cholestasis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related parenteral nutrition-associated cholestasis treatment market.
The major players covered in the parenteral nutrition-associated cholestasis treatment market report are Teva Pharmaceutical Industries Ltd, Zydus Cadila, ALLERGAN, Endo Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett, and Fresenius Kabi AG, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-